Btk Inhibitors as First Oral Atherothrombosis-Selective Antiplatelet Drugs?
In: Thrombosis and Haemostasis, Jg. 119 (2019-05-14), S. 1212-1221
Online
unknown
Zugriff:
Bruton's tyrosine kinase (Btk) is essential for B cell differentiation and proliferation, but also platelets express Btk. Patients with X-linked agammaglobulinemia due to hereditary Btk deficiency do not show bleeding, but a mild bleeding tendency is observed in high dose therapy of B-cell malignancies with ibrutinib and novel second-generation irreversible Btk inhibitors (acalabrutinib and ONO/GS-4059). This review discusses recent studies that may explain this apparent paradox and gives mechanistic insights that suggest a unique potential of low dose irreversible Btk inhibitors as atherothrombosis-focused antiplatelet drugs.
Titel: |
Btk Inhibitors as First Oral Atherothrombosis-Selective Antiplatelet Drugs?
|
---|---|
Autor/in / Beteiligte Person: | Bernlochner, Isabell ; Weber, Christian ; Siess, Wolfgang ; Lorenz, Reinhard ; Busygina, Kristina ; Denzinger, Viola ; RS: Carim - B01 Blood proteins & engineering ; Biochemie ; RS: CARIM - R3.07 - Structure-function analysis of the chemokine interactome for therapeutic targeting and imaging in atherosclerosis |
Link: | |
Zeitschrift: | Thrombosis and Haemostasis, Jg. 119 (2019-05-14), S. 1212-1221 |
Veröffentlichung: | Georg Thieme Verlag KG, 2019 |
Medientyp: | unknown |
ISSN: | 2567-689X (print) ; 0340-6245 (print) |
DOI: | 10.1055/s-0039-1687877 |
Schlagwort: |
|
Sonstiges: |
|